FRANKFURT, Oct 10 (Reuters) - Merck KGaA's Rebif multiple-sclerosis drug is not superior to rival Teva's Copaxone, a study obtained by Reuters on Wednesday showed. "The number of events (relapses) was ...
CAMBRIDGE, Mass.-(BUSINESS WIRE) - Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon ...
CAMBRIDGE, MA – Sept. 11, 2009 – Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results